NASDAQ:CRSP

CRISPR Therapeutics - CRSP Earnings Date, Estimates & Call Transcripts

$65.35

+0.86 (+1.33%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $64.50
▼
$68.06
50-Day Range: $61.10
▼
$81.40
52-Week Range: $42.51
▼
$112.39

Volume: 1.28 million shs
Average Volume: 1.11 million shs
Market Capitalization: $5.10 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $112.33

Upcoming Earnings Date: Nov. 2Estimated
Actual EPS (Aug. 8): -$2.40 Missed By -$0.17
Consensus EPS (Aug. 8): -$2.23
Last Year's Q3 EPS (7/29/2021): $9.44

Earnings Per Share Revenue

CRSP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CRSP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CRISPR Therapeutics Analyst Forecasts

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2022	6	($2.13)	($1.68)	($1.94)
Q2 2022	7	($2.37)	($1.92)	($2.14)
Q3 2022	8	($2.44)	($1.81)	($2.22)
Q4 2022	8	($2.51)	($1.34)	($2.06)
FY 2022	29	($9.45)	($6.75)	($8.36)
Q1 2023	4	($2.55)	($1.86)	($2.21)
Q2 2023	4	($2.74)	($1.88)	($2.34)
Q3 2023	4	($2.92)	($1.90)	($2.30)
Q4 2023	4	($3.23)	($0.07)	($1.26)
FY 2023	16	($11.44)	($5.71)	($8.11)
Q1 2024	1	($2.22)	($2.22)	($2.22)
Q2 2024	1	($1.97)	($1.97)	($1.97)

CRSP Earnings Date and Information

CRISPR Therapeutics last released its quarterly earnings results on August 8th, 2022. The reported ($2.40) earnings per share for the quarter, missing analysts' consensus estimates of ($2.23) by $0.17. The firm earned $0.20 million during the quarter, compared to the consensus estimate of $2.20 million. Its revenue for the quarter was down 100.0% on a year-over-year basis. CRISPR Therapeutics has generated ($8.23) earnings per share over the last year (($8.23) diluted earnings per share). Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($9.26) to ($7.59) per share. CRISPR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 2nd, 2022 based off prior year's report dates.

CRISPR Therapeutics Earnings History by Quarter

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
11/2/2022 (Estimated)
8/8/2022	Q2 2022	($2.23)	($2.40)	($0.17)	($2.40)	$2.20 million	$0.20 million
5/9/2022	Q1 2022	($1.91)	($2.32)	($0.41)	($2.32)	$2.45 million	$0.94 million
2/14/2022	Q4 2021	($1.74)	($1.84)	($0.10)	($1.84)	$5.39 million	$12.90 million
11/3/2021	9/30/2021	($1.75)	($1.67)	+$0.08	($1.67)	$3.85 million	$0.82 million
7/29/2021	6/30/2021	$3.52	$9.44	+$5.92	$9.44	$678.05 million	$900.70 million
4/26/2021	3/31/2021	($1.47)	($1.51)	($0.04)	($1.51)	$4.99 million	$0.54 million
2/15/2021	12/31/2020	($1.27)	($1.50)	($0.23)	($1.50)	$4.69 million	$0.37 million
11/2/2020	9/30/2020	($1.18)	($1.32)	($0.14)	($1.32)	$2.22 million	$0.15 million
7/27/2020	6/30/2020	($0.95)	($1.30)	($0.35)	($1.30)	$19.77 million	$0.04 million
4/28/2020	3/31/2020	($1.05)	($1.15)	($0.10)	($1.15)	$3.04 million	$0.16 million
2/12/2020	Q4 2019	($0.68)	$0.51	+$1.19	$0.51	$39.08 million	$77.00 million
10/28/2019	Q3	($0.9480)	$2.40	+$3.3480	$2.40	$6.32 million	$211.93 million
7/29/2019	Q2	($0.17)	($1.01)	($0.84)	($1.01)	$47.57 million	$0.32 million
4/29/2019	Q1	($0.90)	($0.93)	($0.03)	($0.93)	$1.50 million	$0.30 million
2/25/2019	Q4 2018	($0.83)	($0.92)	($0.09)	($0.92)	$1.56 million	$0.10 million
11/8/2018	Q3	($0.74)	($1.07)	($0.33)	($1.07)	$2.64 million	$0.56 million
8/8/2018	Q2	($0.6310)	($0.82)	($0.1890)	($0.82)	$1.47 million	$1.09 million
5/9/2018	3/31/2018	($0.67)	($0.62)	+$0.05	($0.62)	$3.64 million	$1.36 million
11/8/2017	Q3	($0.60)	($0.62)	($0.02)	($0.62)	$3.61 million	$2.39 million
8/10/2017	6/30/2017	($0.62)	($0.56)	+$0.06	($0.56)	$3.29 million	$3.60 million
5/11/2017	3/31/2017	($0.60)	($0.54)	+$0.06	($0.54)		$2.70 million
3/10/2017	Q4 2016	($0.38)	($0.40)	($0.02)	($1.20)		$2.34 million
11/22/2016	Q3 2016		($2.77)	($2.77)	($2.77)		$1.55 million

CRISPR Therapeutics Earnings - Frequently Asked Questions

When is CRISPR Therapeutics's earnings date?: CRISPR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 2nd, 2022 based off last year's report dates. Learn more on CRSP's earnings history.
Did CRISPR Therapeutics beat their earnings estimates last quarter?: In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) missed the analysts' consensus estimate of ($2.23) by $0.17 with a reported earnings per share (EPS) of ($2.40). Learn more on analysts' earnings estimate vs. CRSP's actual earnings.

How much revenue does CRISPR Therapeutics generate each year?: CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $914.96 million.
How much profit does CRISPR Therapeutics generate each year?: CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of $377.66 million. CRSP has generated -$8.23 earnings per share over the last four quarters.
What is CRISPR Therapeutics's EPS forecast for next year?: CRISPR Therapeutics's earnings are expected to grow from ($9.26) per share to ($7.59) per share in the next year.

More Earnings Resources from MarketBeat

Earnings Tools:

Earnings By Country:

Latest Articles:

Upcoming Earnings:

Constellation Brands (10/6/2022)
PepsiCo (10/12/2022)
Infosys (10/12/2022)
BlackRock (10/13/2022)
Progressive (10/13/2022)
Taiwan Semiconductor Manufacturing (10/13/2022)
Wells Fargo & Company (10/13/2022)
Citigroup (10/14/2022)
JPMorgan Chase & Co. (10/14/2022)
Morgan Stanley (10/14/2022)

This page (NASDAQ:CRSP) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources